JOHNSON & JOHNSON (JNJ) is a publicly traded company in the Unknown sector. Across all available filings, 33 corporate insiders have executed 1034 transactions totaling $396.2M, demonstrating a bearish sentiment with -$391.1M in net insider flow. The most recent transaction on Feb 9, 2026 involved a transaction of 8,594 shares valued at $0.
No significant insider buying has been recorded for JNJ in the recent period.
No significant insider selling has been recorded for JNJ in the recent period.
Based on recent SEC filings, insider sentiment for JNJ is bearish with an Insider Alignment Score of 1/100 and a net flow of -$391.1M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at JOHNSON & JOHNSON (JNJ) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 33 insiders are actively trading JNJ stock, having executed 1034 transactions in the past 90 days. The most active insider is Alex Gorsky (Executive), who has made 52 transactions totaling $246.6M.
Get notified when executives and directors at JNJ file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Award | 8,594 | $N/A | $0 | |
| Feb 9, 2026 | E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Award | 13,706 | $N/A | $0 | |
| Feb 9, 2026 | J. Decker Robert | VP Corporate Controller | Award | 2,741 | $N/A | $0 | |
| Feb 9, 2026 | Duato Joaquin | Executive | Award | 73,054 | $N/A | $0 | |
| Feb 9, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | Award | 13,706 | $N/A | $0 | |
| Feb 9, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Award | 3,602 | $N/A | $0 | |
| Feb 9, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Award | 4,378 | $N/A | $0 | |
| Feb 9, 2026 | D. Swanson James | EVP, CIO | Award | 9,412 | $N/A | $0 | |
| Feb 9, 2026 | L. Taubert Jennifer | EVP, WWC. Innovative Medicine | Award | 27,412 | $N/A | $0 | |
| Feb 9, 2026 | J. Wolk Joseph | Exec VP, CFO | Award | 37,463 | $N/A | $0 | C-Suite |
| Feb 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Option Exercise | 15,571 | $101.87 | $1.6M | Large |
| Feb 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Payment | 10,335 | $239.99 | $2.5M | Large |
| Feb 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Option Exercise | 15,571 | $101.87 | $1.6M | Large |
| Feb 6, 2026 | E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Option Exercise | 38,945 | $101.87 | $4.0M | Large |
| Feb 6, 2026 | E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Payment | 27,270 | $239.99 | $6.5M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 392 | $393.7M | 37.7% |
Payment(F) | 234 | $336.2M | 32.2% |
Exercise(M) | 304 | $311.2M | 29.8% |
Purchase(P) | 10 | $2.5M | 0.2% |
Discretionary(I) | 1 | $19.2K | 0.0% |
Award(A) | 63 | $0 | 0.0% |
Disposition(D) | 5 | $0 | 0.0% |
Gift(G) | 23 | $0 | 0.0% |
Will Acquisition(W) | 2 | $0 | 0.0% |
Insider selling pressure at JOHNSON & JOHNSON has increased, with 33 insiders executing 1034 transactions across all time. Total sales of $393.7M significantly outpace purchases of $2.5M, resulting in a net outflow of $391.1M. This selling activity appears largely discretionary, which may warrant closer attention from investors.